Close
Solutions
Online Inquiry
Global Services

OncoSolid™ Osteosarcoma Cancer Organoid Model based CAR-T In Vitro Efficacy Assay Service

Online Inquiry

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

Osteosarcoma Cancer and Organoid Models

Osteosarcoma (OS) is a primary bone cancer that often occurs in adolescents and old populations with the features of high heterogeneity, malignant, and high chance of mortality. Osteosarcoma is mesenchymal cells-originated cancer, which differentiates from most epithelial-derived tumors, can metastasize to the lung, and develops strong drug resistance.

Cancer organoids are in vitro models imitating the three-dimensional structure of tumor tissues, retaining the interactions of tumor cells with complex environments, and therefore have become a prevail clinical associated tool for the study of tumor formation and progression and developing effective therapies for treatment.

Osteosarcoma Organoid Models and CAR-T Efficacy Evaluation Services at Creative Biolabs

Creative Biolabs is experienced in organoid establishment and CAR-T construction. Within our cancer organoids platform, we applied advanced techniques and innovative strategies for cancer biology study and immunotherapy development.

Workflow

Scheme of the OS organoid production. Fig.1 Scheme of the OS organoid production. (He, et al., 2020)

Tissue Specimen
  • Primary OS tumor
  • Metastasis OS cells
  • Fresh or cryopreservation specimen
Tissue Processing
  • Minced into small fragments
  • Minced, enzymatically digested, and filtered to get single cells
Culture System
  • Embed in basement membrane
  • Air-liquid interface culture with collagen
  • Microfluidic system

Various Strategies

With increasing knowledge in organoid production, Creative Biolabs helps explore optimal strategies for the establishment of osteosarcoma cancer organoids.

Type Description Features
Single tumor cell-based organoid Single cells are collected from tissues and colonial expansion to organoid culture.
  • Uniformed cell culture;
  • Easy to manipulate comparative assays.
Small tissue pieces-based organoid Minced small fragments are cultured on pre-solidified collagen.
  • Simplified culturing steps;
  • Avoiding enzyme digestion-induced disturbance of tumor architecture and microenvironment.
Microfluidic system-based organoid Apply the advanced microfluidic device for tumor culture in a small volume of channels.
  • Supporting setting various culture conditions;
  • Simulating the important tumor environment of the vasculature

Subtypes of Cancer Organoid Model

  • Patient tumor tissue-derived organoid model
  • Mouse tumor tissue-derived organoid model
  • Pluripotent stem cells derived organoid model

Organoid Characterization

Characterization of organoids using molecular and histological approaches.Fig.2 Characterization of organoids using molecular and histological approaches. (Nam, et al., 2022)

CAR-T Efficacy Test Assay

The physiological-related cancer organoid models are suitable for preclinical tests of the response of developed CAR-T cells in vitro.

  • CAR-T cells are incubated with well-characterized cancer organoids.
  • Co-culture medium is optimized to support the growth of both T cells and organoids.
  • T cell-specific cytotoxicity against tumor organoids can be detected in various readouts.

CAR-T Efficacy Test Assay

Related CAR-T Products and Services at Creative Biolabs

Creative Biolabs is committed to cell therapy development. We provide various CAR-T cell therapy-related products and offer CAR-T development services for osteosarcomas, which are combined with a cancer organoid platform to help you have a complete evaluation of the safety and efficacy of engineered T cells.

Target Antigen Target Description CAR-T Products
GD2 GD2 is a glycosphingolipid that overexpresses on neuroblastoma and osteosarcomas cells and is a promising target for immunotherapies. Anti-GD2 CAR-T

Case Study

Develop Osteosarcoma Cancer Organoid Models from Primary OS Tumor and Lung Metastatic OS
Abstract:
  • Patient-derived osteosarcoma cancer organoids are established by culturing in the extracellular matrix, including collagen and basement matrix.
  • The cancer organoids are formed seven days after seeding and support long-term culturing.
Osteosarcoma cancer organoids mimic the original patient's tumor on morphological and histological characteristics.
Fig.3 Osteosarcoma cancer organoids mimic the original patient's tumor on morphological and histological characteristics. (He, et al., 2020)
T cells are present in cancer organoids as they are distributed in tumor tissue.
Fig.4 T cells are present in cancer organoids as they are distributed in tumor tissue. (He, et al., 2020)

Contact Us

Cancer organoid is an innovative model that introduces great changes to cancer studies. Creative Biolabs provides 2D cancer cell lines, 3D organoid models, as well as animal models for CAR-T in vitro and in vivo efficacy tests. Please contact us for detailed information.

References

  1. He, A.; et al. Organoid culture system for patient-derived lung metastatic osteosarcoma. Medical oncology. 2020, 37(11): 105.
  2. Nam, C.; et al. Genomic and Epigenomic Characterization of Tumor Organoid Models. Cancers. 2022, 14: 4090.
Online Inquiry

For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Key Updates
Newsletter NEWSLETTER

The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders

LEARN MORE NEWSLETTER
New Solution NEW SOLUTION

CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.

LEARN MORE SOLUTION
NOVEL SOLUTION NOVEL TECHNOLOGY

Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.

LEARN MORE NOVEL TECHNOLOGY
NEW TECHNOLOGY NEW SOLUTION

Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.

LEARN MORE SOLUTION
Receive our latest news and insights.